III.c

Hemoptysis

(Fr: hémoptysie isolée). Lone hemoptysis. Hemoptysis presumed to be drug-induced may disclose an underlying airway or pulmonary benign or malignant condition. Hemoptysis is a classic, though inconsistent manifestation of underlying diffuse alveolar hemorrhage or DAH (see under IIIa). Certain drugs do increase the risk of post-procedural (e.g. TBLB, maybe also cryobiopsy) bleeding and need to be withdrawn prior to the procedure

Last update : 07/05/2016
 

Causative drugs

28

Amiodarone

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.r I - Interstitial/parenchymal lung disease
I.r - Amiodarone pulmonary toxicity
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.l II - Pulmonary edema - ARDS - Acute respiratory failure
II.l - Postoperative ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.i VI - Pulmonary vasculopathy
VI.i - Acute pulmonary hypertension
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XI.f XI - Miscellaneous
XI.f - Pseudocyanotic skin discoloration (see also XIa, XIVa, XIVb)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.p XII - Cardiovascular involvement / toxicity
XII.p - QT prolongation
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.m XV - Pulmonary pathology
XV.m - Path: Lymphoid hyperplasia - LIP-pattern
XV.o XV - Pulmonary pathology
XV.o - Path: Endogenous lipoid pneumonia (phospholipidosis)
XV.r XV - Pulmonary pathology
XV.r - Path: Smudged geographic necrosis
XV.ao XV - Pulmonary pathology
XV.ao - Path: Pleuritis, pleural fibrosis
XV.bt XV - Pulmonary pathology
XV.bt - Path: Histiocytic proliferation
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.s XVI - Imaging
XVI.s - Imaging: An area or areas of involvement with high attenuation numbers or metallic density
XVI.aa XVI - Imaging
XVI.aa - Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
XVIII.b XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.b - Eye catcher: Electron-dense area or areas of consolidation on unenhanced CT
XVIII.k XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.k - Eye-catcher: An electron-dense liver on unenhanced CT
XVIII.p XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.p - Eye-catcher: An electron-dense ('white') thyroid
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.e XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages
XIX.f XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages in BAL, pleural fluid, or FNA
XIX.m XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.m - BAL: A normal cell differential
1

Anticoagulants, oral (vitamin K antagonists)

III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
III.e III - Pulmonary hemorrhage
III.e - Pulmonary hematoma
III.k III - Pulmonary hemorrhage
III.k - Epistaxis
IV.j IV - Airway involvement
IV.j - Calcification of tracheobronchial cartilaginous rings
V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion
V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.b VIII - Upper, central, large airway involvement
VIII.b - Hematoma causing upper airway obstruction
VIII.q VIII - Upper, central, large airway involvement
VIII.q - Tongue involvement (edema, hematoma)
VIII.u VIII - Upper, central, large airway involvement
VIII.u - Vocal cord hematoma
VIII.v VIII - Upper, central, large airway involvement
VIII.v - Retropharyngeal hematoma
IX.x IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.x - Thoracic epidural or spinal hematoma
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
XI.k XI - Miscellaneous
XI.k - Esophageal hematoma (may cause chest pain and/or tracheal compression)
XI.am XI - Miscellaneous
XI.am - Rectus abdominis hematoma
XIX.d XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage
XIX.e XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages
2

Aspirin (Salicylate-ASA)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion
VII.b VII - Mediastinal involvement
VII.b - Lymphadenopathy with reactive changes
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.y VIII - Upper, central, large airway involvement
VIII.y - Sinonasal discharge, -blockage, -obstruction
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.q X - Systemic conditions, syndromes and reactions
X.q - Systemic inflammatory response
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
1

Bevacizumab

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
III.g III - Pulmonary hemorrhage
III.g - Bleeding/hemorrhage from preexisting lung tumor
III.h III - Pulmonary hemorrhage
III.h - Major/massive hemoptysis
III.k III - Pulmonary hemorrhage
III.k - Epistaxis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VIII.o VIII - Upper, central, large airway involvement
VIII.o - Perforation of the nasal septum
VIII.ab VIII - Upper, central, large airway involvement
VIII.ab - Tracheal/bronchial fistula
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
1

Catheter ablation for atrial fibrillation

II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
III.h III - Pulmonary hemorrhage
III.h - Major/massive hemoptysis
III.l III - Pulmonary hemorrhage
III.l - Lobar alveolar hemorrhage
IV.z IV - Airway involvement
IV.z - Bronchial wall erosion/hematoma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion
V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.z VI - Pulmonary vasculopathy
VI.z - Pulmonary vein stenosis
VI.ac VI - Pulmonary vasculopathy
VI.ac - Pulmonary infarction
VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
VIII.j VIII - Upper, central, large airway involvement
VIII.j - Laryngeal disorder: dysphonia, hoarseness
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
IX.n IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.n - Vagal nerve injury
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.h XI - Miscellaneous
XI.h - Esophageal tear/rupture/fistula
XI.k XI - Miscellaneous
XI.k - Esophageal hematoma (may cause chest pain and/or tracheal compression)
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.ah XV - Pulmonary pathology
XV.ah - Path: Pulmonary congestion
XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XVI.l XVI - Imaging
XVI.l - Imaging: Peribronchovascular areas of consolidation
XVI.bg XVI - Imaging
XVI.bg - Imaging: Pulmonary vein stenosis
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
1

Cocaine

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Pulmonary edema, cardiogenic
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.o IV - Airway involvement
IV.o - Airway hyperresponsiveness
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.l VI - Pulmonary vasculopathy
VI.l - Acute pulmonary vasoconstriction and PHT
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.i VIII - Upper, central, large airway involvement
VIII.i - Midline destructive lesions
VIII.w VIII - Upper, central, large airway involvement
VIII.w - Uvulitis, uvular edema
IX.k IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.k - Trismus (lockjaw)
IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.x X - Systemic conditions, syndromes and reactions
X.x - Subclinical ANCA positivity
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
X.ad X - Systemic conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis
X.as X - Systemic conditions, syndromes and reactions
X.as - Scleroderma renal crisis
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.y XII - Cardiovascular involvement / toxicity
XII.y - Pneumopericardium
XII.ae XII - Cardiovascular involvement / toxicity
XII.ae - Aortic dissection
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XII.aj XII - Cardiovascular involvement / toxicity
XII.aj - Systemic arterial thrombosis
XII.ap XII - Cardiovascular involvement / toxicity
XII.ap - Coronary artery dissection
XIV.c XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.c - Carboxyhemoglobinemia
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.w XV - Pulmonary pathology
XV.w - Path: Pulmonary edema (see also II/IIa)
XV.aw XV - Pulmonary pathology
XV.aw - Path: Skin vasculopathy/vasculitis
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
1

Marijuana, cannabis (haschish, hash, bang, dab)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VIII.w VIII - Upper, central, large airway involvement
VIII.w - Uvulitis, uvular edema
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.s XI - Miscellaneous
XI.s - Death following inhalation of compound - Sniffing death
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
1

Oil, paraffin, lipids (mineral- or other), aspirated

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.p XV - Pulmonary pathology
XV.p - Path: Exogenous lipoid pneumonia
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze
XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.r XVI - Imaging
XVI.r - Imaging: An area or areas of involvement with low attenuation numbers
XVI.z XVI - Imaging
XVI.z - Imaging: A large nodule or mass
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XIX.h XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.h - BAL: Lipid vacuoles in BAL alveolar macrophages
XIX.j XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.j - BAL: Free exogenous lipids in supernatant
1

Radiation therapy (medium term & late effects)

I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.h IV - Airway involvement
IV.h - Airway necrosis
IV.k IV - Airway involvement
IV.k - Bronchiectasis
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
V.l V - Pleural and/or pericardial involvement
V.l - Malignant pleural mesothelioma
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
V.t V - Pleural and/or pericardial involvement
V.t - The apical cap
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
VI.ab VI - Pulmonary vasculopathy
VI.ab - Pulmonary artery stenosis
VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis
VII.i VII - Mediastinal involvement
VII.i - Mediastinitis
VII.j VII - Mediastinal involvement
VII.j - Compression of mediastinal structures/organs
VII.l VII - Mediastinal involvement
VII.l - Calcification of mediastinal lymph nodes
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.r VIII - Upper, central, large airway involvement
VIII.r - Tracheal necrosis, chondronecrosis, perforation
VIII.ab VIII - Upper, central, large airway involvement
VIII.ab - Tracheal/bronchial fistula
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)
XI.h XI - Miscellaneous
XI.h - Esophageal tear/rupture/fistula
XI.i XI - Miscellaneous
XI.i - Esophageal toxicity
XI.v XI - Miscellaneous
XI.v - Rib fracture
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Pericardial thickening - Constrictive pericarditis
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease, chronic
XII.q XII - Cardiovascular involvement / toxicity
XII.q - Coarctation of the aorta (acquired)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ad XII - Cardiovascular involvement / toxicity
XII.ad - Effusive-constrictive pericarditis
XII.ak XII - Cardiovascular involvement / toxicity
XII.ak - Late left ventricular dysfunction/failure
XII.an XII - Cardiovascular involvement / toxicity
XII.an - Pericardial calcification
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial)
XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer
XIII.j XIII - Neoplastic conditions
XIII.j - Pulmonary synovial sarcoma
XIII.l XIII - Neoplastic conditions
XIII.l - Chondrosarcoma
XVI.bi XVI - Imaging
XVI.bi - Imaging: Hyperlucent lung
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
2

Rituximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.i II - Pulmonary edema - ARDS - Acute respiratory failure
II.i - Flash (fulminate) pulmonary edema
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VIII.x VIII - Upper, central, large airway involvement
VIII.x - Opportunistic large airway infection (bacterial, fungal, viral)
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.n X - Systemic conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.av X - Systemic conditions, syndromes and reactions
X.av - Hypogammaglobulinemia-Antibody deficiency (see under XVIIw)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1